학술논문
Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges
Document Type
article
Author
Débora Dummer Meira; Maria Clara de Castro e Caetano; Matheus Correia Casotti; Aléxia Stefani Siqueira Zetum; André Felipe Monteiro Gonçalves; André Rodrigues Moreira; Augusto Henrique de Oliveira; Fellipe Pesente; Gabriel Mendonça Santana; Daniel de Almeida Duque; Gierleson Santos Cangussu Pereira; Giulia de Souza Cupertino de Castro; Isabele Pagani Pavan; João Pedro Sarcinelli Chagas; José Henrique Borges Bourguignon; Juliana Ribeiro de Oliveira; Karen Ruth Michio Barbosa; Lorena Souza Castro Altoé; Luana Santos Louro; Luiza Poppe Merigueti; Lyvia Neves Rebello Alves; Marlon Ramos Rosado Machado; Maria Luísa Rodrigues Oliveira Roque; Pedro Santana Prates; Sayuri Honorio de Paula Segáua; Taissa dos Santos Uchiya; Thomas Erik Santos Louro; Vinicius Eduardo Daleprane; Yasmin Moreto Guaitolini; Creuza Rachel Vicente; Raquel Silva dos Reis Trabach; Bruno Cancian de Araújo; Eldamária de Vargas Wolfgramm dos Santos; Flávia de Paula; Tiago José S. Lopes; Elizeu Fagundes de Carvalho; Iúri Drumond Louro
Source
Genes, Vol 14, Iss 10, p 1906 (2023)
Subject
Language
English
ISSN
2073-4425
Abstract
Lung cancer is a highly aggressive neoplasm and, despite the development of recent therapies, tumor progression and recurrence following the initial response remains unsolved. Several questions remain unanswered about non-small cell lung cancer (NSCLC): (1) Which patients will actually benefit from therapy? (2) What are the predictive factors of response to MAbs and TKIs? (3) What are the best combination strategies with conventional treatments or new antineoplastic drugs? To answer these questions, an integrative literature review was carried out, searching articles in PUBMED, NCBI-PMC, Google Academic, and others. Here, we will examine the molecular genetics of lung cancer, emphasizing NSCLC, and delineate the primary categories of inhibitors based on their molecular targets, alongside the main treatment alternatives depending on the type of acquired resistance. We highlighted new therapies based on epigenetic information and a single-cell approach as a potential source of new biomarkers. The current and future of NSCLC management hinges upon genotyping correct prognostic markers, as well as on the evolution of precision medicine, which guarantees a tailored drug combination with precise targeting.